Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants

Pharmaceuticals - Switzerland
doi 10.3390/ph3103040
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

APOE-TOMM40 in the Pharmacogenomics of Dementia

Journal of Pharmacogenomics & Pharmacoproteomics
2013English

Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry

Frontiers in Psychiatry
PsychiatryMental Health
2019English

Status, Challenges and Future Trends of Brain Inspired Computing

2015English

CYP2D6 Allele Frequencies, Copy Number Variants, and Tandems in the Population of Hong Kong

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2018English

TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia

Journal of Alzheimer's Disease
GerontologyClinical PsychologyMental HealthPsychiatryGeriatricsMedicineNeuroscience
2012English

Endothelial Function, Folate Pharmacogenomics, and Neurocognition in Psychotic Disorders

Schizophrenia Research
PsychiatryMental HealthBiological Psychiatry
2015English

Pharmacogenomics in the Treatment of Mood Disorders: Strategies and Opportunities for Personalized Psychiatry

EPMA Journal
BiochemistryHealth PolicyDrug Discovery
2017English

Influence of Technology Trends on Future Aircraft Architecture

Journal of Aircraft
Aerospace Engineering
2017English

Neurometabolic Roles of ApoE and LDL-R in Mouse Brain

Journal of Bioenergetics and Biomembranes
PhysiologyCell Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy